Ophthalmic Preparation Patents (Class 424/78.04)
-
Patent number: 8388941Abstract: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being ‘self-preserved’. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.Type: GrantFiled: September 20, 2007Date of Patent: March 5, 2013Assignee: Alcon Research, Ltd.Inventors: Masood A. Chowhan, David J. Keith
-
Publication number: 20130039879Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.Type: ApplicationFiled: October 15, 2012Publication date: February 14, 2013Inventor: Novartis AG
-
Patent number: 8349303Abstract: A topical pharmaceutical composition comprising a pharmaceutical active and a polymer of general formula I or general formula II wherein Ck is a saturated or unsaturated, five, six or seven-membered ring; R is a C1-C3alkyl; n is 1, 2, 3, 4 or 5 and m provides a number average molecular weight of the polymer of from 2000 to 80,000.Type: GrantFiled: April 13, 2010Date of Patent: January 8, 2013Assignee: Bausch & Lomb IncorporatedInventors: Eric Phillips, Jay F. Kunzler, Alok Kumar Awasthi
-
Patent number: 8343471Abstract: The present technology provides a nanoparticulate in-situ gelling vitreous substitute, which is a liquid at room temperature to aid easy administration, such as e.g. through a small needle incision, and forms a gel within the eye, which is hydrophilic in nature, similar to the natural vitreous. The vitreous substitute formulation may include a water-soluble natural or synthetic polymer and a gelling-agent which are blended together in the presence of a cross linker, to form a gel having the properties of the vitreous humor. The process of cross linking and gelation may occur in-situ. This can be achieved by dispensing to the eye, different components of the vitreous substitute in liquid state, along with the cross linking agent.Type: GrantFiled: September 3, 2010Date of Patent: January 1, 2013Assignee: Indian Institute of Technology BombayInventors: Rinti Banerjee, Edmund Carvalho
-
Patent number: 8323630Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: April 14, 2011Date of Patent: December 4, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8323631Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.Type: GrantFiled: July 19, 2011Date of Patent: December 4, 2012Assignee: Novartis AGInventor: David L. Jinkerson
-
Patent number: 8318144Abstract: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention.Type: GrantFiled: December 10, 2007Date of Patent: November 27, 2012Assignee: Alcon Research, Ltd.Inventors: Howard Allen Ketelson, Nathaniel D. McQueen
-
Patent number: 8298595Abstract: A contact lens (4) comprises a solid component capable of imparting shape and structure to said lens, and a liquid component, at least partially contained in the solid component, capable of favoring the compatibility between said lens and the eye of a user of said lens, wherein the liquid component comprises a solution capable of being used as a lachrymal substitute.Type: GrantFiled: February 8, 2010Date of Patent: October 30, 2012Assignee: Safilens S.r.l.Inventor: Alessandro Filippo
-
Patent number: 8298521Abstract: The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.Type: GrantFiled: May 23, 2008Date of Patent: October 30, 2012Assignees: The Regents of the University of California, California Institute of TechnologyInventors: Daniel M. Schwartz, Scott Fraser, Robert H. Grubbs, Justin P. Gallivan, Changjun Yu
-
Publication number: 20120269760Abstract: An eye drop composition comprising a carboxyvinyl polymer and a monoterpene, and having a viscosity from 200 to 100,000 mPa·s. The monoterpene may be at least one selected from the group consisting of menthol, camphor and borneol. The carboxyvinyl polymer content may be from 0.001 to 10 w/v % with respect to the total volume of the eye drop composition, and the monoterpene content may be from 0.0001 to 1 w/v % with respect to the total volume of the eye drop composition.Type: ApplicationFiled: September 29, 2010Publication date: October 25, 2012Inventors: Teiko Akagi, Takayuki Miyano, Motoyoshi Inooka
-
Patent number: 8273362Abstract: Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one non ionic surfactant, the oily core including a prostaglandin selected from the group comprising in particular latanoprost, unoprostone isopropyl, travoprost, bimatoprost, tafluprost, 8-isoprostaglandinE2, or a mixture thereof, for treating ocular hypertension and/or glaucoma. These emulsions have the property to increase the chemical stability of prostaglandins.Type: GrantFiled: October 10, 2005Date of Patent: September 25, 2012Assignee: Novagali Pharma S.A.Inventors: Betty Philips, Séverine Bague, Laura Rabinovich-Guilatt, Grégory Lambert
-
Patent number: 8268299Abstract: The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred.Type: GrantFiled: September 20, 2007Date of Patent: September 18, 2012Assignee: Alcon Research, Ltd.Inventors: Bhagwati P. Kabra, Masood A. Chowhan, L. Wayne Schneider, Wesley Wehsin Han
-
Patent number: 8262948Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.Type: GrantFiled: April 27, 2011Date of Patent: September 11, 2012Assignee: Novartis AGInventors: Walter R. Laredo, Ali E. Akinay
-
Patent number: 8262947Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.Type: GrantFiled: July 2, 2010Date of Patent: September 11, 2012Assignee: Novartis AGInventor: Walter R. Laredo
-
Patent number: 8246949Abstract: The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.Type: GrantFiled: September 27, 2005Date of Patent: August 21, 2012Assignee: Aciont, Inc.Inventors: John Higuchi, S. Kevin Li, William I. Higuchi, Matthew S. Hastings
-
Patent number: 8247461Abstract: An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit.Type: GrantFiled: January 26, 2010Date of Patent: August 21, 2012Inventors: Francis X. Smith, John Randall Tracey
-
Publication number: 20120207701Abstract: Formulations and methods for protecting cell layers and tissues exposed to trauma are disclosed. Different molecular mass fractions of the same polymer can be used to better control the physical and chemical properties of the formulation. In this manner the benefits of both fractions, and not just the benefits of the average of the fractions, can be seen in the formulation.Type: ApplicationFiled: February 14, 2012Publication date: August 16, 2012Inventors: Rolf Bergman, Maria Lundqvist, Stig Mannberg, Björn Lundgren, Robert Shimizu
-
Publication number: 20120148519Abstract: The present invention is directed to an ophthalmic lens integrally formed with a hydrogel, the hydrogel including a copolymer obtained from a composition containing (A) an ionic compound including a cation having a polymerizable functional group, and a fluorine-containing anion (hereinafter, referred to as (A) ionic compound), and (B) a hydrophilic compound having a polymerizable functional group.Type: ApplicationFiled: July 6, 2010Publication date: June 14, 2012Applicant: MENICON CO., LTD.Inventor: Kohsuke Satake
-
Publication number: 20120141408Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof. A method for the mitigation of evaporative corneal dehydration employing the high water content ophthalmic device is also disclosed.Type: ApplicationFiled: February 10, 2012Publication date: June 7, 2012Inventors: Richard I. Blackwell, Joseph C. Salamone, Jay F. Kunzler
-
Publication number: 20120128763Abstract: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.Type: ApplicationFiled: February 2, 2012Publication date: May 24, 2012Inventor: Steven Maskin
-
Publication number: 20120093760Abstract: The present embodiments relate to a novel method of making quaternary ammonium polymers comprising the steps of: a) mixing 1,4-bis-dimethylamino-2-butene, triethanolamine, water and an acid; and b) introducing a 1,4-dihalo-2-butene to the mixture so as to initiate a reaction resulting in the quaternary ammonium polymer.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: Abbott Medical Optics Inc.Inventor: Zhi Jian Yu
-
Patent number: 8147816Abstract: Embodiments of the present invention relate to methods and pharmacological or biological compositions to treat presbyopia in the human eye. According to the embodiments, pharmacological or biological compositions may be applied to or injected into an eye to effect a change in the accommodative ability of the eye by the breaking and reduction of lenticular bonds in the eye that may be responsible for presbyopia. The compositions may be applied in an inactive state and subsequently be activated to achieve a therapeutic effect. The application of energy may be used to either break the oxidized lenticular bonds and/or to activate one or more of the pharmacological or biological agents. The energy may be used in a focus treatment pattern to affect a change in the refractive characteristics of the eye and thereby reduce inherent optical distortions.Type: GrantFiled: November 28, 2007Date of Patent: April 3, 2012Assignee: Encore Health, LLCInventors: Jonathan S. Till, Ronald D. Blum, William R. Burns
-
Publication number: 20120070401Abstract: A composition for promoting wound healing comprises a bioadhesive polymer and a pharmaceutically acceptable liquid medium. Such a composition is applied to a wound to promote healing of the wound. The bioadhesive polymer can be selected from the group consisting of natural or synthetic hydrophilic polymers and hydrogels.Type: ApplicationFiled: August 25, 2011Publication date: March 22, 2012Inventors: Jinzhong Zhang, Keith W. Ward, Francisco J. Lopez, Matthew Jonasse
-
Publication number: 20120070402Abstract: The present invention relates to artificial tear formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a cis-diol such as sorbitol that interferes with the cross-linking of galactomannan and borate. Optionally, the formulations are substantially free of divalent cations.Type: ApplicationFiled: November 22, 2011Publication date: March 22, 2012Applicant: ALCON RESEARCH, LTD.Inventors: Howard Allen Ketelson, James W. Davis, David L. Meadows
-
Publication number: 20120064123Abstract: The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles (Nanopids™), aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use.Type: ApplicationFiled: September 9, 2010Publication date: March 15, 2012Inventor: Assad S. Sawaya
-
Patent number: 8119112Abstract: Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C16alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.Type: GrantFiled: September 3, 2008Date of Patent: February 21, 2012Assignee: Bausch & Lomb IncorporatedInventors: Erning Xia, Susan E. Burke, Srini Venkatesh, Vicki Barniak
-
Patent number: 8106151Abstract: A ophthalmic composition, comprising: an aqueous liquid medium, and an effective amount of polyquaternium-1 made by a process of: a) mixing 1,4-bis-dimethylamino-2-butene, triethanolamine and an acid; b) introducing a 1,4-dichloro-2-butene to the mixture, and c) isolating polyquaternium-1 having a molecular weight as determined by a proton NMR method of about 10,000 or more, at a yield of at least about 50%.Type: GrantFiled: January 25, 2010Date of Patent: January 31, 2012Assignee: Abbot Medical Optics Inc.Inventor: Zhi-Jian Yu
-
Patent number: 8092838Abstract: Topical administration of a generator of H2S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intraocular pressure in normotensive, conscious albino rabbits indicating a similar role for H2S in the regulation of aqueous humor dynamics in animals and humans. H2S donors, NaHS and Na2S, inhibited field-stimulated [3H]NE release from porcine isolated iris-ciliary bodies and produced relaxation of pre-contracted iris muscle strips indicating a pharmacological role for H2S in the anterior uvea. The observation that donors of H2S can alter sympathetic neurotransmission and induce an inhibitory action on iris smooth muscle suggests that this gas has the potential to influence several physiological/pathological processes in the eye. The ability of NaHS or Na2S to inhibit [3H]NE release mimics the well-established action some antiglaucoma drugs (e.g.Type: GrantFiled: May 1, 2006Date of Patent: January 10, 2012Assignees: The University of Houston System, Board of Regents of the University of Nebraska, Creighton UniversityInventors: Sunny Edet Ohia, Catherine Atieno Opere, Guilin Zhan, Emmanuel Monjok, Kaustubh Kulkami, Ghislaine E. Kouamou
-
Patent number: 8084501Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.Type: GrantFiled: January 20, 2006Date of Patent: December 27, 2011Assignees: Breath Limited, Resolution Chemicals LimitedInventors: Victor Deaciuc, Michael Hagan, Hashem Heiati, Karen K. Jette, Gary C. Visor, Ian G. C. McAffer, Peter Tasko
-
Publication number: 20110274725Abstract: Biocompatible, triggerable degradation, polymerizable hydrogels, uses and delivery devices are disclosed. These hydrogels are at least substantially water soluble macromers, having a variety of uses especially for ocular therapy. The macromers include at least one water soluble region, at least one region which is degradable via a triggering event, usually by hydrolysis, and at least two free radical-polymerizable regions. The regions can, in some embodiments, be both water soluble and trigger able degradable. The macromers are polymerized by exposure of the polymerizable regions to free radicals generated by photosensitive chemicals and dyes. An advantage of these polymer hydrogels is that they can be polymerized rapidly in an aqueous surrounding. Precisely conforming, semi-permeable, biodegradable films or membranes can thus be formed on tissue in situ to serve as biodegradable barriers, as carriers for living cells or other biologically active materials, and as surgical adhesives for the eye.Type: ApplicationFiled: September 16, 2009Publication date: November 10, 2011Inventors: Louis Breton, Jeffrey Katz, Mark Banister
-
Publication number: 20110262519Abstract: Ophthalmic stabilized lenses have improved rotational properties by treating them with a wetting agent after they are at least initially polymerized.Type: ApplicationFiled: April 20, 2011Publication date: October 27, 2011Inventors: Ross Franklin, Jonathan Hansen, Kurt Moody
-
Patent number: 8043607Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.Type: GrantFiled: July 10, 2009Date of Patent: October 25, 2011Assignee: Novartis AGInventor: David L. Jinkerson
-
Publication number: 20110223126Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.Type: ApplicationFiled: May 20, 2011Publication date: September 15, 2011Inventors: Yasuko MATSUMURA, Kazuhiro Fukushima
-
Patent number: 7999063Abstract: A multipurpose solution for contact lens care, comprising: an aqueous liquid medium; a quaternary ammonium polymer having an average molecular weight as determined by the proton NMR method of at least 22 k, and methods for making.Type: GrantFiled: April 23, 2009Date of Patent: August 16, 2011Assignee: Abbott Medical Optics Inc.Inventor: Zhi-Jian Yu
-
Patent number: 7999064Abstract: A multipurpose solution for contact lens care, comprising: an aqueous liquid medium; a quaternary ammonium polymer having an average molecular weight as determined by the proton NMR method of at least 28 k, and methods for making the same.Type: GrantFiled: April 23, 2009Date of Patent: August 16, 2011Assignee: Abbott Medical Optics Inc.Inventor: Zhi-Jian Yu
-
Patent number: 7993634Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: GrantFiled: December 15, 2005Date of Patent: August 9, 2011Assignee: Allergan, Inc.Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
-
Patent number: 7985405Abstract: A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed.Type: GrantFiled: September 17, 2002Date of Patent: July 26, 2011Inventor: Jin Jun Zhang
-
Patent number: 7976833Abstract: An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells.Type: GrantFiled: October 10, 2006Date of Patent: July 12, 2011Assignee: Aspen Biomedical Research, LLCInventor: David B. Soll
-
Patent number: 7973081Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.Type: GrantFiled: July 27, 2007Date of Patent: July 5, 2011Assignee: Novagali Pharma SAInventors: Laura Rabinovich-Guilatti, Gregory Lambert, Frederic Lallemand, Betty Philips
-
Publication number: 20110135743Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.Type: ApplicationFiled: December 1, 2010Publication date: June 9, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, Wesley Wehsin Han
-
Patent number: 7935332Abstract: This invention effects a change in the accommodation of the human lens affected by presbyopia through the use of various reducing agents that change accommodative abilities of the human lens, and/or by applying energy to affect a change in the accommodative abilities of the human lens. This invention both prevents the onset of presbyopia as well as treats it. By breaking and/or preventing the formation of bonds that adhere lens fibers together causing hardening of the lens, the present invention increases the elasticity and distensibility of the lens and/or lens capsule.Type: GrantFiled: December 14, 2004Date of Patent: May 3, 2011Assignee: Encore Health, LLCInventor: Jonathan S. Till
-
Patent number: 7914803Abstract: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of three polymers that have a synergistic effect on viscosity.Type: GrantFiled: February 9, 2007Date of Patent: March 29, 2011Assignee: Alcon, Inc.Inventors: Masood A. Chowhan, Huagang Chen
-
Publication number: 20110059039Abstract: The use of poly(oxyethylene)-poly(oxybutylene) block copolymers in pharmaceutical compositions useful for modifying the surfaces of contact lenses and other medical devices is disclosed. The present invention is based in-part on a discovery that this class of compounds is particularly efficient in wetting hydrophobic surfaces, such as the surfaces of silicone hydrogel contact lenses and other types of ophthalmic lenses. Such compounds are also useful for cleaning purposes. The use of the compounds as surfactants in various types of compositions for treating contact lenses therefore represents a preferred embodiment of the present invention.Type: ApplicationFiled: November 16, 2010Publication date: March 10, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Howard Allen Ketelson, Nathaniel D. McQueen
-
Patent number: 7897553Abstract: A polymeric biguanide composition comprising less than 18 mol % of terminal amine groups as measured by 13C NMR. The polymeric biguanide composition also is characterized by a relative increase in the molar concentration of terminal guanidine groups or terminal cyanoguanidino groups. The invention is also directed to ophthalmic compositions comprising the polymeric biguanide compositions. The polymeric biguanide compositions can be used as an antimicrobial component in an ophthalmic lens care solution, or as a preservative to in a pharmaceutical composition or other health care product.Type: GrantFiled: October 2, 2007Date of Patent: March 1, 2011Assignee: Bausch & Lomb IncorporatedInventor: David J. Heiler
-
Publication number: 20110027214Abstract: The present embodiments relate to a novel method of making quaternary ammonium polymers comprising the steps of: a) mixing 1,4-bis-dimethylamino-2-butene, triethanolamine, water and an acid; and b) introducing a 1,4-dihalo-2-butene to the mixture so as to initiate a reaction resulting in the quaternary ammonium polymer.Type: ApplicationFiled: January 25, 2010Publication date: February 3, 2011Applicant: Abbott Medical Optics Inc.Inventor: Zhi-Jian Yu
-
Publication number: 20110027215Abstract: Tissue adhesives formed by crosslinking albumin and/or gelatin with certain polyamines and/or polycarboxylates using a water-soluble carbodiimide are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described.Type: ApplicationFiled: October 14, 2010Publication date: February 3, 2011Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventor: Henry Keith CHENAULT
-
Patent number: 7875270Abstract: A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed.Type: GrantFiled: December 17, 2004Date of Patent: January 25, 2011Assignee: Abbott Medical Optics Inc.Inventor: Jin Jun Zhang
-
Patent number: 7875271Abstract: The present invention provides an ophthalmic composition containing xanthan gum and glucose, which has a superior corneal epithelial disorder-treating effect.Type: GrantFiled: March 23, 2007Date of Patent: January 25, 2011Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Koji Doi, Hiroshi Aki
-
Patent number: 7871602Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.Type: GrantFiled: October 3, 2008Date of Patent: January 18, 2011Assignee: Alcon, Inc.Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
-
Publication number: 20110008276Abstract: The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.Type: ApplicationFiled: July 7, 2010Publication date: January 13, 2011Applicant: ALCON RESEARCH, LTD.Inventors: James W. Davis, Howard Allen Ketelson, David L. Meadows